nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—PTGS1—Etoposide—muscle cancer	0.167	0.218	CbGbCtD
Rosiglitazone—CYP1A2—Dacarbazine—muscle cancer	0.152	0.199	CbGbCtD
Rosiglitazone—SLCO1B1—Methotrexate—muscle cancer	0.15	0.197	CbGbCtD
Rosiglitazone—CYP2C8—Etoposide—muscle cancer	0.0961	0.126	CbGbCtD
Rosiglitazone—ALB—Methotrexate—muscle cancer	0.0822	0.108	CbGbCtD
Rosiglitazone—CYP1A2—Etoposide—muscle cancer	0.0744	0.0975	CbGbCtD
Rosiglitazone—CYP2D6—Doxorubicin—muscle cancer	0.0418	0.0548	CbGbCtD
Rosiglitazone—PPARG—hindlimb—muscle cancer	0.0134	0.125	CbGeAlD
Rosiglitazone—PPARG—appendage—muscle cancer	0.0115	0.107	CbGeAlD
Rosiglitazone—PPARG—Teniposide—Etoposide—muscle cancer	0.0112	1	CbGdCrCtD
Rosiglitazone—ACSL4—renal system—muscle cancer	0.00644	0.0598	CbGeAlD
Rosiglitazone—ACSL4—cardiac atrium—muscle cancer	0.00577	0.0536	CbGeAlD
Rosiglitazone—ACSL4—tendon—muscle cancer	0.00503	0.0467	CbGeAlD
Rosiglitazone—ACSL4—bone marrow—muscle cancer	0.00487	0.0452	CbGeAlD
Rosiglitazone—ACSL4—vagina—muscle cancer	0.00466	0.0433	CbGeAlD
Rosiglitazone—ACSL4—head—muscle cancer	0.00431	0.04	CbGeAlD
Rosiglitazone—ACSL4—testis—muscle cancer	0.00416	0.0387	CbGeAlD
Rosiglitazone—PPARG—embryo—muscle cancer	0.00383	0.0356	CbGeAlD
Rosiglitazone—SLCO1B1—renal system—muscle cancer	0.00336	0.0312	CbGeAlD
Rosiglitazone—Haematocrit decreased—Methotrexate—muscle cancer	0.00317	0.0269	CcSEcCtD
Rosiglitazone—PPARG—smooth muscle tissue—muscle cancer	0.00301	0.028	CbGeAlD
Rosiglitazone—PPARG—renal system—muscle cancer	0.0029	0.0269	CbGeAlD
Rosiglitazone—CYP2A6—vagina—muscle cancer	0.00246	0.0229	CbGeAlD
Rosiglitazone—PPARG—tendon—muscle cancer	0.00226	0.021	CbGeAlD
Rosiglitazone—Hepatic failure—Dactinomycin—muscle cancer	0.0022	0.0186	CcSEcCtD
Rosiglitazone—PPARG—bone marrow—muscle cancer	0.00219	0.0204	CbGeAlD
Rosiglitazone—PPARG—vagina—muscle cancer	0.0021	0.0195	CbGeAlD
Rosiglitazone—Multiple fractures—Methotrexate—muscle cancer	0.00203	0.0172	CcSEcCtD
Rosiglitazone—Fracture—Methotrexate—muscle cancer	0.00203	0.0172	CcSEcCtD
Rosiglitazone—Hepatic failure—Vincristine—muscle cancer	0.00196	0.0167	CcSEcCtD
Rosiglitazone—PPARG—head—muscle cancer	0.00194	0.018	CbGeAlD
Rosiglitazone—CYP2C8—renal system—muscle cancer	0.00191	0.0177	CbGeAlD
Rosiglitazone—PPARG—testis—muscle cancer	0.00187	0.0174	CbGeAlD
Rosiglitazone—CYP1A2—renal system—muscle cancer	0.00179	0.0166	CbGeAlD
Rosiglitazone—ALB—testis—muscle cancer	0.00176	0.0163	CbGeAlD
Rosiglitazone—PTGS1—smooth muscle tissue—muscle cancer	0.00161	0.0149	CbGeAlD
Rosiglitazone—CYP2C19—vagina—muscle cancer	0.00158	0.0147	CbGeAlD
Rosiglitazone—Cardiac failure congestive—Etoposide—muscle cancer	0.00158	0.0134	CcSEcCtD
Rosiglitazone—PTGS1—renal system—muscle cancer	0.00155	0.0144	CbGeAlD
Rosiglitazone—Pleural effusion—Methotrexate—muscle cancer	0.00154	0.0131	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00151	0.0128	CcSEcCtD
Rosiglitazone—Cardiac failure—Etoposide—muscle cancer	0.00146	0.0124	CcSEcCtD
Rosiglitazone—Hyperlipidaemia—Doxorubicin—muscle cancer	0.00142	0.012	CcSEcCtD
Rosiglitazone—PTGS1—cardiac atrium—muscle cancer	0.00139	0.0129	CbGeAlD
Rosiglitazone—CYP2C8—vagina—muscle cancer	0.00138	0.0129	CbGeAlD
Rosiglitazone—Hepatitis—Dactinomycin—muscle cancer	0.00137	0.0116	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Vincristine—muscle cancer	0.00134	0.0114	CcSEcCtD
Rosiglitazone—Pleural effusion—Doxorubicin—muscle cancer	0.00133	0.0113	CcSEcCtD
Rosiglitazone—Myocardial infarction—Vincristine—muscle cancer	0.00133	0.0113	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.0013	0.011	CcSEcCtD
Rosiglitazone—Erythema multiforme—Dactinomycin—muscle cancer	0.00129	0.011	CcSEcCtD
Rosiglitazone—CYP2D6—renal system—muscle cancer	0.00127	0.0118	CbGeAlD
Rosiglitazone—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00125	0.0106	CcSEcCtD
Rosiglitazone—CYP2C8—testis—muscle cancer	0.00123	0.0115	CbGeAlD
Rosiglitazone—PTGS1—tendon—muscle cancer	0.00121	0.0112	CbGeAlD
Rosiglitazone—Connective tissue disorder—Vincristine—muscle cancer	0.0012	0.0102	CcSEcCtD
Rosiglitazone—Cardiac disorder—Vincristine—muscle cancer	0.00113	0.00961	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00112	0.00953	CcSEcCtD
Rosiglitazone—PTGS1—vagina—muscle cancer	0.00112	0.0104	CbGeAlD
Rosiglitazone—Anaemia—Dactinomycin—muscle cancer	0.0011	0.00933	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00109	0.00927	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Etoposide—muscle cancer	0.00109	0.00921	CcSEcCtD
Rosiglitazone—Myocardial infarction—Etoposide—muscle cancer	0.00108	0.00916	CcSEcCtD
Rosiglitazone—Leukopenia—Dactinomycin—muscle cancer	0.00106	0.00903	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Methotrexate—muscle cancer	0.00105	0.00891	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Etoposide—muscle cancer	0.00104	0.00884	CcSEcCtD
Rosiglitazone—PTGS1—head—muscle cancer	0.00104	0.00963	CbGeAlD
Rosiglitazone—Back pain—Vincristine—muscle cancer	0.00103	0.00872	CcSEcCtD
Rosiglitazone—Myalgia—Dactinomycin—muscle cancer	0.00101	0.00859	CcSEcCtD
Rosiglitazone—PTGS1—testis—muscle cancer	0.001	0.0093	CbGeAlD
Rosiglitazone—Diabetes mellitus—Methotrexate—muscle cancer	0.000984	0.00835	CcSEcCtD
Rosiglitazone—Anaemia—Vincristine—muscle cancer	0.000982	0.00833	CcSEcCtD
Rosiglitazone—Oedema—Dactinomycin—muscle cancer	0.000971	0.00824	CcSEcCtD
Rosiglitazone—Fluid retention—Doxorubicin—muscle cancer	0.000969	0.00823	CcSEcCtD
Rosiglitazone—Infection—Dactinomycin—muscle cancer	0.000964	0.00818	CcSEcCtD
Rosiglitazone—Hepatic failure—Methotrexate—muscle cancer	0.000953	0.00808	CcSEcCtD
Rosiglitazone—Leukopenia—Vincristine—muscle cancer	0.000951	0.00807	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Dactinomycin—muscle cancer	0.00095	0.00806	CcSEcCtD
Rosiglitazone—Erythema multiforme—Etoposide—muscle cancer	0.000935	0.00793	CcSEcCtD
Rosiglitazone—Eye disorder—Etoposide—muscle cancer	0.000924	0.00784	CcSEcCtD
Rosiglitazone—Cardiac disorder—Etoposide—muscle cancer	0.000918	0.00779	CcSEcCtD
Rosiglitazone—Hypertension—Vincristine—muscle cancer	0.000917	0.00779	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Doxorubicin—muscle cancer	0.000909	0.00771	CcSEcCtD
Rosiglitazone—Myalgia—Vincristine—muscle cancer	0.000905	0.00768	CcSEcCtD
Rosiglitazone—Immune system disorder—Etoposide—muscle cancer	0.000893	0.00758	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000884	0.0075	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Methotrexate—muscle cancer	0.000874	0.00741	CcSEcCtD
Rosiglitazone—Oedema—Vincristine—muscle cancer	0.000867	0.00736	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Vincristine—muscle cancer	0.000867	0.00736	CcSEcCtD
Rosiglitazone—Infection—Vincristine—muscle cancer	0.000861	0.00731	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—muscle cancer	0.000852	0.00723	CcSEcCtD
Rosiglitazone—CYP2D6—head—muscle cancer	0.000852	0.00791	CbGeAlD
Rosiglitazone—Nervous system disorder—Vincristine—muscle cancer	0.00085	0.00722	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Vincristine—muscle cancer	0.000849	0.00721	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000848	0.0072	CcSEcCtD
Rosiglitazone—Fatigue—Dactinomycin—muscle cancer	0.000837	0.0071	CcSEcCtD
Rosiglitazone—Back pain—Etoposide—muscle cancer	0.000833	0.00707	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—muscle cancer	0.000825	0.007	CcSEcCtD
Rosiglitazone—CYP2D6—testis—muscle cancer	0.000823	0.00764	CbGeAlD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000817	0.00694	CcSEcCtD
Rosiglitazone—Anaemia—Etoposide—muscle cancer	0.000796	0.00675	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00079	0.0067	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—muscle cancer	0.000789	0.0067	CcSEcCtD
Rosiglitazone—Leukopenia—Etoposide—muscle cancer	0.00077	0.00654	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—muscle cancer	0.00076	0.00645	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—muscle cancer	0.00076	0.00645	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000756	0.00642	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Vincristine—muscle cancer	0.000749	0.00635	CcSEcCtD
Rosiglitazone—Fatigue—Vincristine—muscle cancer	0.000748	0.00634	CcSEcCtD
Rosiglitazone—Hypertension—Etoposide—muscle cancer	0.000743	0.00631	CcSEcCtD
Rosiglitazone—Constipation—Vincristine—muscle cancer	0.000742	0.00629	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Etoposide—muscle cancer	0.000702	0.00596	CcSEcCtD
Rosiglitazone—Infection—Etoposide—muscle cancer	0.000698	0.00592	CcSEcCtD
Rosiglitazone—Asthenia—Dactinomycin—muscle cancer	0.000696	0.00591	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Etoposide—muscle cancer	0.000688	0.00584	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000688	0.00584	CcSEcCtD
Rosiglitazone—Diarrhoea—Dactinomycin—muscle cancer	0.000664	0.00564	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Doxorubicin—muscle cancer	0.000663	0.00563	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000654	0.00555	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Methotrexate—muscle cancer	0.000624	0.0053	CcSEcCtD
Rosiglitazone—Asthenia—Vincristine—muscle cancer	0.000622	0.00528	CcSEcCtD
Rosiglitazone—Rash—Dactinomycin—muscle cancer	0.000612	0.00519	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Etoposide—muscle cancer	0.000606	0.00515	CcSEcCtD
Rosiglitazone—Fatigue—Etoposide—muscle cancer	0.000606	0.00514	CcSEcCtD
Rosiglitazone—Constipation—Etoposide—muscle cancer	0.000601	0.0051	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000595	0.00505	CcSEcCtD
Rosiglitazone—Diarrhoea—Vincristine—muscle cancer	0.000593	0.00504	CcSEcCtD
Rosiglitazone—Hepatitis—Methotrexate—muscle cancer	0.000592	0.00503	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—muscle cancer	0.000583	0.00495	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—muscle cancer	0.000578	0.0049	CcSEcCtD
Rosiglitazone—Nausea—Dactinomycin—muscle cancer	0.000576	0.00489	CcSEcCtD
Rosiglitazone—Dizziness—Vincristine—muscle cancer	0.000573	0.00487	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000566	0.00481	CcSEcCtD
Rosiglitazone—Erythema multiforme—Methotrexate—muscle cancer	0.00056	0.00475	CcSEcCtD
Rosiglitazone—Urticaria—Etoposide—muscle cancer	0.000558	0.00474	CcSEcCtD
Rosiglitazone—Eye disorder—Methotrexate—muscle cancer	0.000553	0.0047	CcSEcCtD
Rosiglitazone—Cardiac disorder—Methotrexate—muscle cancer	0.00055	0.00466	CcSEcCtD
Rosiglitazone—Rash—Vincristine—muscle cancer	0.000547	0.00464	CcSEcCtD
Rosiglitazone—Dermatitis—Vincristine—muscle cancer	0.000546	0.00464	CcSEcCtD
Rosiglitazone—Headache—Vincristine—muscle cancer	0.000543	0.00461	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00054	0.00459	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—muscle cancer	0.000536	0.00455	CcSEcCtD
Rosiglitazone—Immune system disorder—Methotrexate—muscle cancer	0.000535	0.00454	CcSEcCtD
Rosiglitazone—Malnutrition—Methotrexate—muscle cancer	0.000516	0.00438	CcSEcCtD
Rosiglitazone—Nausea—Vincristine—muscle cancer	0.000515	0.00437	CcSEcCtD
Rosiglitazone—Hepatitis—Doxorubicin—muscle cancer	0.000513	0.00435	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—muscle cancer	0.000505	0.00429	CcSEcCtD
Rosiglitazone—Asthenia—Etoposide—muscle cancer	0.000504	0.00428	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—muscle cancer	0.000504	0.00428	CcSEcCtD
Rosiglitazone—Back pain—Methotrexate—muscle cancer	0.000499	0.00423	CcSEcCtD
Rosiglitazone—Pruritus—Etoposide—muscle cancer	0.000497	0.00422	CcSEcCtD
Rosiglitazone—Erythema multiforme—Doxorubicin—muscle cancer	0.000485	0.00411	CcSEcCtD
Rosiglitazone—Diarrhoea—Etoposide—muscle cancer	0.000481	0.00408	CcSEcCtD
Rosiglitazone—Eye disorder—Doxorubicin—muscle cancer	0.000479	0.00407	CcSEcCtD
Rosiglitazone—Anaemia—Methotrexate—muscle cancer	0.000476	0.00404	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—muscle cancer	0.000476	0.00404	CcSEcCtD
Rosiglitazone—Dizziness—Etoposide—muscle cancer	0.000465	0.00394	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—muscle cancer	0.000463	0.00393	CcSEcCtD
Rosiglitazone—Leukopenia—Methotrexate—muscle cancer	0.000461	0.00392	CcSEcCtD
Rosiglitazone—Malnutrition—Doxorubicin—muscle cancer	0.000446	0.00379	CcSEcCtD
Rosiglitazone—Rash—Etoposide—muscle cancer	0.000443	0.00376	CcSEcCtD
Rosiglitazone—Dermatitis—Etoposide—muscle cancer	0.000442	0.00376	CcSEcCtD
Rosiglitazone—Headache—Etoposide—muscle cancer	0.00044	0.00373	CcSEcCtD
Rosiglitazone—Myalgia—Methotrexate—muscle cancer	0.000439	0.00372	CcSEcCtD
Rosiglitazone—Arthralgia—Methotrexate—muscle cancer	0.000439	0.00372	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—muscle cancer	0.000432	0.00366	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Methotrexate—muscle cancer	0.000421	0.00357	CcSEcCtD
Rosiglitazone—Infection—Methotrexate—muscle cancer	0.000418	0.00355	CcSEcCtD
Rosiglitazone—Nausea—Etoposide—muscle cancer	0.000417	0.00354	CcSEcCtD
Rosiglitazone—Nervous system disorder—Methotrexate—muscle cancer	0.000413	0.0035	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—muscle cancer	0.000413	0.0035	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Methotrexate—muscle cancer	0.000412	0.0035	CcSEcCtD
Rosiglitazone—Leukopenia—Doxorubicin—muscle cancer	0.0004	0.00339	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—muscle cancer	0.000385	0.00327	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000383	0.00325	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—muscle cancer	0.00038	0.00323	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—muscle cancer	0.00038	0.00323	CcSEcCtD
Rosiglitazone—Oedema—Doxorubicin—muscle cancer	0.000364	0.00309	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—muscle cancer	0.000364	0.00309	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000363	0.00308	CcSEcCtD
Rosiglitazone—Fatigue—Methotrexate—muscle cancer	0.000363	0.00308	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—muscle cancer	0.000362	0.00307	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—muscle cancer	0.000357	0.00303	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—muscle cancer	0.000357	0.00303	CcSEcCtD
Rosiglitazone—Urticaria—Methotrexate—muscle cancer	0.000334	0.00284	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000332	0.00282	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000315	0.00267	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—muscle cancer	0.000314	0.00267	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—muscle cancer	0.000312	0.00264	CcSEcCtD
Rosiglitazone—Asthenia—Methotrexate—muscle cancer	0.000302	0.00256	CcSEcCtD
Rosiglitazone—Pruritus—Methotrexate—muscle cancer	0.000298	0.00253	CcSEcCtD
Rosiglitazone—Urticaria—Doxorubicin—muscle cancer	0.000289	0.00246	CcSEcCtD
Rosiglitazone—Diarrhoea—Methotrexate—muscle cancer	0.000288	0.00244	CcSEcCtD
Rosiglitazone—Dizziness—Methotrexate—muscle cancer	0.000278	0.00236	CcSEcCtD
Rosiglitazone—Rash—Methotrexate—muscle cancer	0.000265	0.00225	CcSEcCtD
Rosiglitazone—Dermatitis—Methotrexate—muscle cancer	0.000265	0.00225	CcSEcCtD
Rosiglitazone—Headache—Methotrexate—muscle cancer	0.000264	0.00224	CcSEcCtD
Rosiglitazone—Asthenia—Doxorubicin—muscle cancer	0.000261	0.00222	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—muscle cancer	0.000258	0.00219	CcSEcCtD
Rosiglitazone—Nausea—Methotrexate—muscle cancer	0.00025	0.00212	CcSEcCtD
Rosiglitazone—Diarrhoea—Doxorubicin—muscle cancer	0.000249	0.00212	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—muscle cancer	0.000241	0.00204	CcSEcCtD
Rosiglitazone—Rash—Doxorubicin—muscle cancer	0.00023	0.00195	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—muscle cancer	0.00023	0.00195	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—muscle cancer	0.000228	0.00194	CcSEcCtD
Rosiglitazone—Nausea—Doxorubicin—muscle cancer	0.000216	0.00184	CcSEcCtD
